Brief: Aptose Presents New Preclinical Cg-806 Data At The 2019 Ash Annual Meeting

Aptose Biosciences

09/12/2019 19:57

Dec 9 (Reuters) - Aptose Biosciences Inc  APS.TO :
    * APTOSE PRESENTS NEW PRECLINICAL CG-806 DATA AT THE 2019 ASH ANNUAL MEETING
    * APTOSE - CG-806 BROADLY INHIBITS B-CELL RECEPTOR SIGNALING IN CLL CELLS,
RESULTING IN CLL CELL APOPTOSIS AND REDUCED PROLIFERATION
    * APTOSE - CG-806 IS MORE POTENT THAN IBRUTINIB TO INDUCE APOPTOSIS OF MEC1
CLL
CELLS
    * CG-806 DEMONSTRATED SUPERIOR ANTI-LYMPHOMA EFFECTS COMPARED WITH IBRUTINIB
    * APTOSE - OVER 50% OF PATIENTS WITH CLL AND MCL DISCONTINUE IBRUTINIB
TREATMENT
DUE TO INTOLERANCE OR EMERGENCE OF REFRACTORY OR RESISTANT DISEASE

Source text for Eikon:  ID:nGNX9XRXJp 
Further company coverage:  APS.TO 

 ((Reuters.Briefs@thomsonreuters.com;))